GLONGHUI, January 17 | When receiving research from institutional investors, Sains (688480.SH) recently said that sales of Zijin Pharmaceuticals are less affected by seasonal fluctuations. They mainly sell products in batches. There are phased sales, and revenue fluctuations are mainly delivery issues. If some customers increase production capacity and the amount required for initial production is high, it will lead to higher sales. The increase in sales in the fourth quarter of 2023 is mainly due to the large number of orders placed during the current period due to the fact that some major customers have reached the replenishment cycle.